- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07847008
Evaluation of a Brief, Scalable Module to Mitigate Suicidal Ideation Among Youth (Phase 2)
This project embeds the "Give to Others" (GO) talk therapy module in a standard, outpatient therapy protocol to demonstrate target engagement in the context of ongoing clinical care and testing the ability of the GO module to engage the target in a rigorous randomized controlled trial (RCT) of the intervention. We will target perceived burdensomeness (PB) among 80 clinic-referred youths (ages 12-17) who experience subacute suicidal ideation (SI; i.e., positive suicide risk screen; stable safety status).
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Youths will be recruited from the FIU Center for Children and Families (CCF) waitlist and the community at large, and will be randomized to one of the following 2 arms: a 12-session talk therapy and suicide risk management condition (control arm); and a 12-session therapy and suicide risk management condition plus the GO module (active arm). We hypothesize that youths receiving the GO module will have lower levels of PB and burden-related interpretation bias at mid-treatment and post-treatment compared with youths who receive the control arm. We also hypothesize that youths receiving the GO module will have lower levels of PB and burden-related interpretation bias at midtreatment and posttreatment compared to pre-treatment levels.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jeremy Pettit, PhD
- Telefoonnummer: 305-348-1671
- E-mail: jpettit@fiu.edu
Studie Contact Back-up
- Naam: Victor Buitron, PhD
- Telefoonnummer: 305-348-9880
- E-mail: vbuitron@fiu.edu
Studie Locaties
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33199
- FIU Center for Children and Families
-
Hoofdonderzoeker:
- Victor Buitron, PhD
-
Contact:
- Jeremy Pettit, PhD
- Telefoonnummer: 305-348-1671
- E-mail: jpettit@fiu.edu
-
Contact:
- Victor Buitron, PhD
- Telefoonnummer: 305-348-9880
- E-mail: vbuitron@fiu.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria
Adolescents must:
- be between ages 12 and 17 years
- score at or above the clinical cutoff on the Revised Child Anxiety and Depression Scale
- score at or above 4 on the Interpersonal Needs Questionnaire- Burdensomeness Scale
- have a positive screen for suicide risk (i.e., endorsement of suicidal ideation via self-report)
- be fluent in English and have available a parent who is fluent in English or Spanish
Exclusion Criteria
For adolescents to be excluded, they must:
- have cognitive impairment or developmental delay which does not allow for the completion of basic study procedures (i.e., reading and filling out questionnaires; talking to a clinician)
- show imminent risk or a history of hurting themselves or others requiring intensive and restrictive services
- be involved currently in a psychosocial treatment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: GO arm
Safety Planning + MATCH + GO module |
Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction. The GO Module is a brief cognitive behavioral intervention targeting youth burden-related beliefs. It consists of one primary session and brief follow-up. The MATCH Anxiety and Depression modules involve a transdiagnostic protocol that adapts to individual clinical needs for teens experiencing internalizing symptoms. Participants receive weekly cognitive-behavioral therapy sessions guided by manualized decision flowcharts to sequence treatment strategies. |
|
Actieve vergelijker: Comparison Arm
Safety Planning + MATCH |
Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction. The MATCH Anxiety and Depression modules involve a transdiagnostic protocol that adapts to individual clinical needs for teens experiencing internalizing symptoms. Participants receive weekly cognitive-behavioral therapy sessions guided by manualized decision flowcharts to sequence treatment strategies. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Interpersonal Needs Questionnaire- Burdensomenes Scale- Self-report at Mid-treatment
Tijdsspanne: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
5-item youth self-ratings on perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome). |
From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
|
Suicide Risk and Ideation Scale for Kids (S-RISK) - Child Report at Mid-Treatment
Tijdsspanne: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
The S-RISK measures the severity and intensity of suicidal thoughts and capability via 20 items. Higher scores indicate higher severity of suicide risk. |
From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
|
Interpersonal Needs Questionnaire- Burdensomenes Scale- Self-report at Post-treatment
Tijdsspanne: From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
5-item youth self-ratings on perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome). |
From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
|
Suicide Risk and Ideation Scale for Kids (S-RISK) - Child Report at Post-Treatment
Tijdsspanne: From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
The S-RISK measures the severity and intensity of suicidal thoughts and capability via 20 items. Higher scores indicate higher severity of suicide risk. |
From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Interpersonal Needs Questionnaire- Burdensomenes Scale- Parent report at Mid-Treatment
Tijdsspanne: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
5-item parent ratings on youth perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome). |
From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
|
Sentence Completion Task- Liability Index at Mid-Treatment
Tijdsspanne: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
28-item youth completed task assessing burden-related interpretation bias. Participants read 28 sentences indicative of posing a liability on others and select negatively- or positively-valenced words to complete each sentence. Each item is scored 0 or 1, yielding a total score between 0 and 28. Higher scores indicate higher levels of burden interpretation bias (worse outcome). |
From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
|
Momentary Perceived Burdensomeness (mPB) Scale at Mid-Treatment
Tijdsspanne: From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
The mPB scale was developed to capture real-time states of perceived burdensomeness (Lühr et al., 2026). mPB includes two self-report items rated 1 to 5 with higher scores indicating higher levels of burdensomeness. |
From pre-treatment to mid-treatment (within one week of completing the assigned intervention at the midpoint of CBT)
|
|
Interpersonal Needs Questionnaire- Burdensomenes Scale- Parent report at Post-Treatment
Tijdsspanne: From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
5-item parent ratings on youth perceived burdensomeness over the past week. Each item is scored 1-7 (1 = not at all true for me; 7 = very true for me), yielding a total between 5 and 35. Higher scores indicate higher levels of perceived burdensomeness (worse outcome). |
From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
|
Sentence Completion Task- Liability Index at Post-Treatment
Tijdsspanne: From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
28-item youth completed task assessing burden-related interpretation bias. Participants read 28 sentences indicative of posing a liability on others and select negatively- or positively-valenced words to complete each sentence. Each item is scored 0 or 1, yielding a total score between 0 and 28. Higher scores indicate higher levels of burden interpretation bias (worse outcome). |
From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
|
Momentary Perceived Burdensomeness (mPB) Scale at Post-Treatment
Tijdsspanne: From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
The mPB scale was developed to capture real-time states of perceived burdensomeness (Lühr et al., 2026). mPB includes two self-report items rated 1 to 5 with higher scores indicating higher levels of burdensomeness. |
From pre-treatment to post-treatment (within one week of completing the final CBT session)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Victor Buitron, PhD, Florida International University
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRB-26-0416
- R33MH137300 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
We will submit deidentified raw data to the National Institute of Mental Health (NIMH) Data Archive (NDA). The NDA is a data repository run by the NIMH that allows researchers studying mental health to collect and share deidentified information with each other. Our local data files will be coded, meaning we can track data back to subjects via a master key. However, we will upload de-identified electronic raw data collected from questionnaires and interviews to the NDA.
IPD-tijdsbestek voor delen
The scientific community will have access to data when the award ends. NDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .